November 28, 2025BMC CancerOpen Access

Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA

View Full Paper

Ask AI

Bookmark

Recurrence risk prediction shows promise for melanoma patients with early-stage disease, enhancing management.
Key findings indicate that circulating tumor DNA may serve as a significant biomarker in clinical assessment.
Analysis of biomarkers for melanoma recurrence utilizes innovative approaches to improve therapeutic strategies.
Highlights the importance of disease monitoring in guiding treatment for patients with resected melanoma.

Implication

Observational analysis calculates recurrence risk in melanoma patients, suggesting potential personalized therapeutic strategies.

Abstract

Identification of clinical and genetic biomarkers for recurrence risk prediction in resected melanoma may aid in clinical decision-making for early disease monitoring and optimal design of therapeutic strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/6928f126a65b730b9ea7a47e https://doi.org/10.1186/s12885-025-15093-w

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis calculates recurrence risk in melanoma patients, suggesting potential personalized therapeutic strategies.

Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA

Key Points

Implication

Abstract

Discussion

Cite This Study

Recurrence risk prediction in resected stage I-III melanoma utilizing circulating tumor DNA

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading